These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 8525694)

  • 1. Efficient purification and rigorous characterisation of a recombinant gp120 for HIV vaccine studies.
    Jones DH; McBride BW; Roff MA; Farrar GH
    Vaccine; 1995 Aug; 13(11):991-9. PubMed ID: 8525694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glycoform and net charge heterogeneity in gp120 immunogens used in HIV vaccine trials.
    Yu B; Morales JF; O'Rourke SM; Tatsuno GP; Berman PW
    PLoS One; 2012; 7(8):e43903. PubMed ID: 22928048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonaffinity purification of recombinant gp120 for use in AIDS vaccine development.
    Scandella CJ; Kilpatrick J; Lidster W; Parker C; Moore JP; Moore GK; Mann KA; Brown P; Coates S; Chapman B
    AIDS Res Hum Retroviruses; 1993 Dec; 9(12):1233-44. PubMed ID: 8142140
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody to native human immunodeficiency virus type 1 envelope glycoproteins induced by IIIB and MN recombinant gp120 vaccines. The NIAID AIDS Vaccine Evaluation Group.
    Gorse GJ; Patel GB; Newman FK; Belshe RB; Berman PW; Gregory TJ; Matthews TJ
    Clin Diagn Lab Immunol; 1996 Jul; 3(4):378-86. PubMed ID: 8807200
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of cross-reactive cytotoxic T-lymphocyte responses specific for HIV-1 gp120 using saponin adjuvant (QS-21) supplemented subunit vaccine formulations.
    Newman MJ; Wu JY; Gardner BH; Anderson CA; Kensil CR; Recchia J; Coughlin RT; Powell MF
    Vaccine; 1997 Jun; 15(9):1001-7. PubMed ID: 9261947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MN and IIIB recombinant glycoprotein 120 vaccine-induced binding antibodies to native envelope glycoprotein of human immunodeficiency virus type 1 primary isolates. National Institute of Allergy and Infectious Disease Aids Vaccine Evaluation Group.
    Gorse GJ; Patel GB; Mandava M; Berman PW; Belshe RB
    AIDS Res Hum Retroviruses; 1999 Jul; 15(10):921-30. PubMed ID: 10408729
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a Stable MGAT1
    Doran RC; Yu B; Wright M; O'Rourke SM; Yin L; Richardson JM; Byrne G; Mesa KA; Berman PW
    Front Immunol; 2018; 9():2313. PubMed ID: 30344523
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Salivary binding antibodies induced by human immunodeficiency virus type 1 recombinant gp120 vaccine. The NIAID AIDS Vaccine Evaluation Group.
    Gorse GJ; Yang EY; Belshe RB; Berman PW
    Clin Diagn Lab Immunol; 1996 Nov; 3(6):769-73. PubMed ID: 8914773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV-1MN recombinant glycoprotein 160 vaccine-induced cellular and humoral immunity boosted by HIV-1MN recombinant glycoprotein 120 vaccine. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group.
    Gorse GJ; Corey L; Patel GB; Mandava M; Hsieh RH; Matthews TJ; Walker MC; McElrath MJ; Berman PW; Eibl MM; Belshe RB
    AIDS Res Hum Retroviruses; 1999 Jan; 15(2):115-32. PubMed ID: 10029244
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Construction and immunogenicity of Salmonella typhimurium vaccine vectors that express HIV-1 gp120.
    Fouts TR; Tuskan RG; Chada S; Hone DM; Lewis GK
    Vaccine; 1995 Dec; 13(17):1697-705. PubMed ID: 8719522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Generation and characterization of a bivalent protein boost for future clinical trials: HIV-1 subtypes CR01_AE and B gp120 antigens with a potent adjuvant.
    Wen Y; Trinh HV; Linton CE; Tani C; Norais N; Martinez-Guzman D; Ramesh P; Sun Y; Situ F; Karaca-Griffin S; Hamlin C; Onkar S; Tian S; Hilt S; Malyala P; Lodaya R; Li N; Otten G; Palladino G; Friedrich K; Aggarwal Y; LaBranche C; Duffy R; Shen X; Tomaras GD; Montefiori DC; Fulp W; Gottardo R; Burke B; Ulmer JB; Zolla-Pazner S; Liao HX; Haynes BF; Michael NL; Kim JH; Rao M; O'Connell RJ; Carfi A; Barnett SW
    PLoS One; 2018; 13(4):e0194266. PubMed ID: 29698406
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of V3-specific cleavage of recombinant HIV-1 gp120 produced in Chinese hamster ovary cells.
    Du SX; Xu L; Viswanathan S; Whalen RG
    Protein Expr Purif; 2008 Jun; 59(2):223-31. PubMed ID: 18406166
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV-Exposed Infants Vaccinated with an MF59/Recombinant gp120 Vaccine Have Higher-Magnitude Anti-V1V2 IgG Responses than Adults Immunized with the Same Vaccine.
    McGuire EP; Fong Y; Toote C; Cunningham CK; McFarland EJ; Borkowsky W; Barnett S; Itell HL; Kumar A; Gray G; McElrath MJ; Tomaras GD; Permar SR; Fouda GG
    J Virol; 2018 Jan; 92(1):. PubMed ID: 29021402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An HIV Envelope gp120-Fc Fusion Protein Elicits Effector Antibody Responses in Rhesus Macaques.
    Shubin Z; Li W; Poonia B; Ferrari G; LaBranche C; Montefiori D; Zhu X; Pauza CD
    Clin Vaccine Immunol; 2017 Jun; 24(6):. PubMed ID: 28404572
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the immune response to recombinant gp120 in humans and chimpanzees.
    Berman PW; Eastman DJ; Wilkes DM; Nakamura GR; Gregory TJ; Schwartz D; Gorse G; Belshe R; Clements ML; Byrn RA
    AIDS; 1994 May; 8(5):591-601. PubMed ID: 7520248
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity of a polyvalent HIV-1 candidate vaccine based on fourteen wild type gp120 proteins in golden hamsters.
    Azizi A; Anderson DE; Ghorbani M; Gee K; Diaz-Mitoma F
    BMC Immunol; 2006 Oct; 7():25. PubMed ID: 17076905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of low-profile serine substitutions in the V3 loop of HIV-1 gp120 IIIB/LAI on the immunogenicity of the envelope protein.
    Peet NM; McKeating JA; de Souza JB; Roitt IM; Delves PJ; Lund T
    Virology; 1998 Nov; 251(1):59-70. PubMed ID: 9813203
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of a single-shot subunit vaccine for HIV-1.
    Cleland JL; Powell MF; Lim A; Barrón L; Berman PW; Eastman DJ; Nunberg JH; Wrin T; Vennari JC
    AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S21-6. PubMed ID: 7865303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cellular and humoral immune responses to a canarypox vaccine containing human immunodeficiency virus type 1 Env, Gag, and Pro in combination with rgp120.
    AIDS Vaccine Evaluation Group 022 Protocol Team
    J Infect Dis; 2001 Feb; 183(4):563-70. PubMed ID: 11170981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity and HIV-1 virus neutralization of MN recombinant glycoprotein 120/HIV-1 QS21 vaccine in baboons .
    Powell MF; Cleland JL; Eastman DJ; Lim A; Murthy K; Newman MJ; Nunberg JH; Weissburg RP; Vennari JC; Wrin T
    AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S105-8. PubMed ID: 7865282
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.